Lymphocyte subsets with the lowest decline at baseline and the slow lowest rise during recovery in COVID-19 critical illness patients with diabetes mellitus.
Adult
Aged
Antigens, CD19
B-Lymphocytes
Betacoronavirus
CD3 Complex
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes
CD56 Antigen
CD8-Positive T-Lymphocytes
COVID-19
Comorbidity
Coronavirus Infections
/ blood
Critical Illness
Diabetes Complications
/ blood
Diabetes Mellitus
/ metabolism
Disease Progression
Female
Humans
Killer Cells, Natural
Length of Stay
Lymphocyte Count
Lymphocyte Subsets
Lymphocytes
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ blood
Prognosis
Retrospective Studies
SARS-CoV-2
Severity of Illness Index
T-Lymphocyte Subsets
Coronavirus disease 2019 (COVID-19)
Diabetes mellitus
Dynamic change
Lymphocyte subsets
Journal
Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
21
04
2020
revised:
06
05
2020
accepted:
02
07
2020
pubmed:
25
7
2020
medline:
6
10
2020
entrez:
25
7
2020
Statut:
ppublish
Résumé
Host dysregulation of immune response was highly involved in the pathological process of Coronavirus disease 2019 (COVID-19), especially COVID-19 severe cases with DM. In this study we aimed at the dynamic change of peripheral lymphocyte and subsets during COVID-19 covery. The peripheral lymphocyte and subsets of 95 confirmed cases with COVID-19 from baseline to four weeks were compared between critical illness and non-critical illness cases with or without DM. The dynamic characteristics of lymphocyte and subsets in COVID-19 patients was that it reduced significantly at one week, rapidly elevated to the peak at two weeks after onset, then gradually declined during recovery. The COVID-19 critical illness patients with DM had the lowest decline at one week and the slow lowest rise at two weeks after onset, while COVID-19 non-critical illness patients with DM had the rapid highest rise at two weeks after onset, both of them had similar lymphocyte and subsets at five weeks after onset and lower than those patients without DM. These findings provide a reference for clinicians that for COVID-19 patients with DM and the lowest decline of lymphocyte and subsets, immunomodulatory therapy as soon as possible might avoid or slow down disease progression; moreover for COVID-19 critical illness patients with or without DM and non-critical illness patients with DM, continuous immunomodulatory therapy in later stages of disease might speed up virus clearance, shorten hospital stay, improve disease prognosis in COVID-19 critical illness patients with DM.
Sections du résumé
BACKGROUND
BACKGROUND
Host dysregulation of immune response was highly involved in the pathological process of Coronavirus disease 2019 (COVID-19), especially COVID-19 severe cases with DM.
AIM
OBJECTIVE
In this study we aimed at the dynamic change of peripheral lymphocyte and subsets during COVID-19 covery.
METHODS
METHODS
The peripheral lymphocyte and subsets of 95 confirmed cases with COVID-19 from baseline to four weeks were compared between critical illness and non-critical illness cases with or without DM.
RESULTS
RESULTS
The dynamic characteristics of lymphocyte and subsets in COVID-19 patients was that it reduced significantly at one week, rapidly elevated to the peak at two weeks after onset, then gradually declined during recovery. The COVID-19 critical illness patients with DM had the lowest decline at one week and the slow lowest rise at two weeks after onset, while COVID-19 non-critical illness patients with DM had the rapid highest rise at two weeks after onset, both of them had similar lymphocyte and subsets at five weeks after onset and lower than those patients without DM.
CONCLUSIONS
CONCLUSIONS
These findings provide a reference for clinicians that for COVID-19 patients with DM and the lowest decline of lymphocyte and subsets, immunomodulatory therapy as soon as possible might avoid or slow down disease progression; moreover for COVID-19 critical illness patients with or without DM and non-critical illness patients with DM, continuous immunomodulatory therapy in later stages of disease might speed up virus clearance, shorten hospital stay, improve disease prognosis in COVID-19 critical illness patients with DM.
Identifiants
pubmed: 32707212
pii: S0168-8227(20)30593-3
doi: 10.1016/j.diabres.2020.108341
pmc: PMC7373679
pii:
doi:
Substances chimiques
Antigens, CD19
0
CD3 Complex
0
CD56 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108341Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no competing interests.
Références
Biochem J. 2005 Nov 15;392(Pt 1):135-43
pubmed: 16048439
J Immunol Res. 2019 Apr 7;2019:6491738
pubmed: 31089478
Rev Med Liege. 2018 Jul;73(7-8):370-375
pubmed: 30113776
Vaccine. 2016 Apr 12;34(17):2008-14
pubmed: 26954467
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Viruses. 2012 May;4(5):833-46
pubmed: 22754651
Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43
pubmed: 26124093
N Engl J Med. 2020 Apr 30;382(18):1677-1679
pubmed: 32109012
J Virol. 2014 Oct;88(19):11034-44
pubmed: 25056892
Adv Exp Med Biol. 2019;1197:107-117
pubmed: 31732938
Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5
pubmed: 24599590
Int J Mol Sci. 2019 Jul 10;20(14):
pubmed: 31295952
J Virol. 2010 Feb;84(3):1289-301
pubmed: 19906920
Expert Rev Respir Med. 2014 Feb;8(1):25-42
pubmed: 24325586
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
J Med Virol. 2020 Apr;92(4):433-440
pubmed: 31967321
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940